Isotechnika ends existing license accord with ILJIN

Isotechnika Pharma (TSX:ISA) has exercised its right to terminate an existing development, distribution and license agreement with ILJIN Life Science of South Korea and is pursuing discussions to potentially change the current relationship with ILJIN in order to better advance its voclosporin program. As a result, Isotechnika has secured full rights to voclosporin for transplant [...]

ILJIN considering control position in Isotechnika

ILJIN Life Science of South Korea, the second largest shareholder of Isotechnika Pharma (TSX:ISA), has verbally informed Isotechnika’s board that ILJIN is planning to “increase their level of control within the company.” The verbal proposal was made by Daniel Park, Executive VP of ILJIN, who has resigned his position as Chief Business Officer of Isotechnika, [...]

Isotechnika in license pact with Vifor Pharma

Isotechnika Pharma (TSX:ISA) has signed a global development and commercialization license agreement with Vifor Pharma, a member of the Swiss Galenica Group, for its lead drug, voclosporin, for the treatment of lupus and all proteinuric nephrology indications, covering the U.S. and other regions outside of Canada, South Africa, Israel, China, Taiwan and Hong Kong. While [...]

Donald Wyatt joins Isotechnika board

Donald Wyatt, the founder of consultancy The Wyatt Group, has been appointed a director of Isotechnika Pharma (TSX:ISA), serving as a representative of 3SBio (NASDAQ:SSRX), a Chinese biotech company. Mr. Wyatt is currently an advisor to 3SBio. He replaces Dr. David Chen, COO of 3SBio, who recently has taken on additional responsibilities that make it [...]

Isotechnika names Daniel Park as CBO

Isotechnika Pharma (TSX:ISA) has appointed Daniel Park to the role of chief business officer, reporting directly to CEO Dr. Robert Foster. Mr. Park will oversee all business development operations at Isotechnika, and will specifically help to lead licensing and partnership discussions and negotiations for voclosporin. He will also maintain his position as executive VP of [...]

Isotechnika receives financing for Phase 3 trial

Isotechnika Pharma (TSX:ISA) has finalized the development, distribution and license agreement with ILJIN Life Science, a member of the ILJIN Group of South Korea, in order to finance a pivotal Phase 3 trial of voclosporin for the prevention of kidney transplant rejection. Isotechnika will now receive a license fee of $4.5-million plus proceeds of $2.375-million from [...]

Paladin, Isotechnika submit Voclera in Canada

Paladin Labs (TSX:PLB) and Isotechnika (TSX:ISA) have submitted Voclera, a treatment for moderate to severe psoriasis, for marketing approval in Canada. Voclera was discovered by Isotechnika and has been in development since the late 1990s. Paladin acquired the Canadian rights for Voclera from Isotechnika in June, 2009. “This submission is the culmination of almost 15 years [...]

Isotechnika licenses voclosporin to ILJIN Life

Isotechnika Pharma (TSX:ISA) has entered into a development, distribution and licence agreement with ILJIN Life Science, a member of the ILJIN Group of South Korea, for the further clinical and commercial development of its voclosporin drug. Isotechnika has granted ILJIN an exclusive license to voclosporin for transplant and autoimmune indications for the U.S. and other [...]

Isotechnika and 3SBio ink licence deal

Isotechnika Pharma (TSX:ISA) and 3SBio, Inc., a Chinese biotechnology company, have signed a development and commercialization agreement for Isotechnika’s voclosporin drug to prevent organ rejection following transplantation and to treat autoimmune diseases. Under the accord, Isotechnika will receive $6 million (U.S.), consisting of an upfront licensing payment of $1.5 million and an additional $4.5 million [...]

Lux-Isotechnika get complete response letter from FDA

Isotechnika Pharma’s (TSX:ISA) partner, Lux Biosciences, has received a complete response letter from the FDA about its new drug application for voclosporin in the treatment of non-infectious uveitis, involving the intermediate or posterior segments of the eye. The FDA has requested additional information and recommended that an additional clinical trial be conducted in order to [...]